A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Phase 1 Completed 29 enrolled Eli Lilly and Company AstraZeneca · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC).

Timeline

Start: 2016-10-24
Primary completion: 2017-10-19
Completion: 2022-05-09

Publications

Yu HA, Paz-Ares LG, Yang JC, Lee KH, Garrido P, Park K, Kim JH, Lee DH, Mao H, Wijayawardana SR, Gao L, Hozak RR, Chao BH, Planchard D. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer. Clin Cancer Res. 2021 Feb 15;27(4):992-1002. doi: 10.1158/1078-0432.CCR-20-1690. Epub 2020 Oct 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Necitumumab	Monoclonal antibody	800 mg	Intravenous
Subject	Ramucirumab	Monoclonal antibody	10 mg/kg	Intravenous
Background	Osimertinib	Small molecule	80 mg	Oral

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Summary

Timeline

Publications

Drugs

Indications